- In April 2024, AbbVie launched a new FDA-approved injectable submental fat treatment formulation designed to offer faster fat reduction with fewer sessions. This advancement reflects AbbVie’s commitment to improving patient outcomes and expanding its portfolio in non-invasive aesthetic treatments, reinforcing its leadership position in the global submental fat treatment market
- In March 2024, Candela Corporation introduced an advanced cryolipolysis device featuring optimized cooling technology for enhanced submental fat reduction. The device aims to deliver more effective and comfortable treatments with reduced downtime, catering to growing patient demand for non-surgical double chin contouring solutions worldwide
- In February 2024, Cynosure LLC launched a combination therapy protocol integrating laser and injectable treatments for submental fat, offering synergistic benefits in fat reduction and skin tightening. This innovative approach targets both fat cells and skin laxity, appealing to a broader patient base and setting new standards in aesthetic practice
- In January 2024, Inmode Ltd. expanded its platform with a radiofrequency-assisted lipolysis device specifically designed for submental fat treatment. The new technology provides minimally invasive options with precise targeting and enhanced safety, supporting the rising demand for effective, low-risk facial contouring procedures
- In December 2023, BTL unveiled a novel ultrasound-based submental fat reduction system, featuring real-time imaging to optimize treatment precision. This launch underscores BTL’s focus on integrating cutting-edge technology to improve efficacy and patient satisfaction in the non-surgical aesthetics market
